The first study will look at a regimen based on Merck's recently-approved oral NS3/NS4a inhibitor Victrelis (boceprevir) alongside Roche's investigational NS5B inhibitor mericitabine (RO5024048) and already-marketed drugs Pegasys (peginterferon alfa-2a) and Copegus (ribavirin).
The phase II study - called DYNAMO 1 - will enrol adult patients with HCV genotype 1 infection who have failed to respond to prior treatment with peginterferon alfa/ribavirin therapy.
Read more....
0 comments:
Post a Comment